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Abstract
p53 is a tumor suppressor protein that prevents tumorigenesis through cell cycle arrest or apoptosis of cells in response to
cellular stress such as DNA damage. Because the oncoprotein MDM2 interacts with p53 and inhibits its activity, MDM2-p53
interaction has been a major target for the development of anticancer drugs. While previous studies have used phage
display to identify peptides (such as DI) that inhibit the MDM2-p53 interaction, these peptides were not sufficiently
optimized because the size of the phage-displayed random peptide libraries did not cover all of the possible sequences. In
this study, we performed selection of MDM2-binding peptides from large random peptide libraries in two stages using
mRNA display. We identified an optimal peptide named MIP that inhibited the MDM2-p53 and MDMX-p53 interactions 29-
and 13-fold more effectively than DI, respectively. Expression of MIP fused to the thioredoxin scaffold protein in living cells
by adenovirus caused stabilization of p53 through its interaction with MDM2, resulting in activation of the p53 pathway.
Furthermore, expression of MIP also inhibited tumor cell proliferation in a p53-dependent manner more potently than DI.
These results show that two-stage, mRNA-displayed peptide selection is useful for the rapid identification of potent
peptides that target oncoproteins.
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Introduction
p53 is a tumor suppressor protein that prevents tumorigenesis
[1], [2]. By responding to cellular stress such as DNA damage,
expression levels of p53 increase, and the upregulated p53
transactivates various targets involved in antitumor activities such
as cyclin-dependent kinase inhibitor p21
WAF1/CIP1 and the pro-
apoptotic protein Puma [3], [4]. Consequently, p53 induces cell
cycle arrest or apoptosis in cells that have genetic aberrations, and
as such, inactivation of p53 leads to accumulation of the
aberrations that may cause overexpression of several kinds of
oncoproteins, resulting in tumorigenesis [5]. p53 retains its wild-
type status in approximately 50% of human cancers. Therefore,
inactivation of p53 is caused by interaction with the E3 ubiquitin
ligase MDM2 [6]–[8]. MDM2 acts as an essential regulator of p53
stability and activity by forming a negative feedback loop [9].
Several studies have shown that abrogating the MDM2-p53
interaction leads to reactivation of the p53 pathway and inhibition
of tumor cell proliferation [10,11]. The crystal structure of the
MDM2-p53 complex revealed that the N-terminal portion of
p5315–29 is important in binding to MDM2, and several small-
molecule compounds or peptides mimicking the MDM2 binding
site of p53 antagonize MDM2 and activate the p53 pathway in
cancer cells [12]–[15]. Therefore, the MDM2-p53 interaction is a
potent target of anticancer drug design [16], [17].
Peptides are powerful tools for disrupting protein-protein
interactions because the large interacting surfaces and the high
specificity of these peptides lead to fewer adverse side effects
when used as pharmaceutical agents [18], [19]. As previously
reported, several peptides that inhibit the MDM2-p53 interaction
have been identified from randomized peptide libraries using
phage display [20], [21]. Hu et al. identified a 12-amino-acid (aa)
peptide (LTFEHYWAQLTS), DI, that could inhibit not only the
MDM2-p53 interaction but also the MDMX-p53 interaction
more effectively than Nutlin-3, a small molecular inhibitor of the
MDM2-p53 interaction [10], [12]. An MDM2 homologue,
MDMX is highly expressed in tumors which also binds to and
negatively regulates p53 [12]. Furthermore, DI expressed with
recombinant adenovirus as a thioredoxin-fused protein could
activate the p53 pathway both in vitro and in vivo. However, DI
was not sufficiently optimized because it was selected by phage
display from a 12-mer random library (4.1610
15 possible
members) with a size of ,10
8 that did not cover all of the
possible sequences.
To overcome this problem, we performed in vitro selection of
MDM2-binding peptides from random peptide libraries using
mRNA display [22], [23]. This system based on cell-free
translation is a potent method for screening large peptide libraries
(,10
13 unique members) that can cover all of the possible
sequences in a 10-mer random library. In this study, we applied
mRNA display to identify a highly optimized peptide that could
disrupt the MDM2-p53 complex from a random library
containing all of the possible sequences by dividing the selection
process into two stages. We also verified that a selected peptide
could inhibit the MDM2-p53 interaction in living cells and block
tumor cell growth.
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The 1st selection of a 16-mer randomized peptide library
To obtain novel peptides capable of disrupting the MDM2-p53
complex using mRNA display (Fig. 1), we first constructed a 16-mer
randomized peptide library encodedby (NNS)16 codons (N = A, T,
G or C; S = G or C) because the crystal structure of the MDM2-
p53 complex has revealed that the 15-aa residue of p5315–29 is
important for binding to MDM2 [24]. As the bait protein, we used
MDM27–300 fused to the TAP tag [25], which contains the IgG
bindingdomainofproteinA (ZZdomain), a TEVproteasecleavage
site and a calmodulin binding peptide for immobilization on IgG
beads and specific elution of the MDM2-binding peptide from
beads during the affinity selection. After four rounds of selection for
binding to the beads immobilizing the TAP-tagged MDM2, the
resulting library was cloned and sequenced. Consequently, 33
peptide sequences were identified (Fig. 2A). More than half of all
peptides retained the three hydrophobic residues corresponding to
Phe19, Trp23, and Leu26 of wild-type p53. Three of the 33
peptides, X16-1, X16-5 and X16-9, were frequently obtained.
Furthermore, DNA sequences of clones X16-1 and X16-9 were
quite similar to those of X16-2 to X16-4 and X16-10, respectively,
suggesting that these peptides were generated from acquired point
mutations during RT-PCR in the selection.
To examine the ability of the peptides to bind to MDM2, we
constructed plasmids for the expression of GFP-fused peptides and
performed pull-down assays between the GFP-fused peptides and
MDM2 (Fig. S1). Consequently, binding to MDM2 immobilized
on beads was clearly detected for GFP-X16-1, X16-2, X16-5 and
X16-9 but not for GFP-p5313–28 and GFP alone, suggesting that
the affinity of the 16-mer peptides obtained from the selection was
higher than that of wild-type p53. As previously reported,
inhibition of the MDM2-p53 interaction leads to activation of
the p53 pathway [10], [13], [14]. However, expression of these
GFP-fused 16-mer peptides did not activate the p53 pathway in
living cells (data not shown), suggesting that the ability of these
peptides to bind to MDM2 or inhibit the MDM2-p53 interaction
was insufficient.
The 2nd selection of a 12-mer partially randomized
peptide library
While the mRNA display selection system could select 10
12–
10
13 molecules at once, it could cover at most 10
27–10
28 of the
possible sequences in the 16-mer randomized library (,10
20).
Therefore, these 16-mer peptides required further optimization.
To improve the efficiency of the selection strategy, we performed a
2nd selection. The results from the prior selection suggest that
three hydrophobic residues corresponding to Phe19, Trp23, and
Leu26 of wild-type p53 are quite important in binding to MDM2,
consistent with previous reports [24]. Additionally, on the basis of
the findings that the 12-mer peptides obtained by phage display
could tightly bind to MDM2 [12], [20], [21], we speculated that
peptides of 12 aa residues were sufficient to antagonize MDM2
function. Thus, we constructed a 12-mer partially randomized
library containing the three fixed hydrophobic residues encoded
by the (NNS)2-TTC-(NNS)3-TGG-(NNS)2-TTA-(NNS)2 codons
whose 5.1610
11 possible members were covered by the library size
of mRNA display.
During the 2nd selection step, we found that enrichment of
specific peptide sequences was difficult due to an abundance of
molecules that bound to MDM2 in the library. This difficulty arose
from the fixed key residues and the large library size of mRNA
display. We therefore increased the stringency of the selection
process to enrich for specific peptide sequences during the 2nd
selection by shortening the binding time from 2 h to 5 min and
increasing the number of washes from 3 to 15. After five rounds of
the improved affinity selection, the amounts of the mRNA-
displayed peptides that bound to the TAP-tagged MDM2 were
saturated, and the resulting library was subsequently cloned and
sequenced. The results show that sequences of 10 of the 83 peptides
obtained from the library after the fifth rounds of selection were
identical and were obtained most frequently (Fig. 2B). Therefore,
the peptide X12-1 was identified as an optimized peptide for
disrupting the MDM2-p53 complex and named MIP (MDM2
Inhibitory Peptide). In addition to the 16-mer peptides, GFP-MIP
could bind to TAP-tagged MDM2 immobilized on beads (Fig. 3A).
We used MIP for further functional analyses.
Figure 1. Schematic representation of in vitro selection of MDM2-binding peptides using mRNA display. (1) A DNA library encoding
randomized peptides is transcribed. (2) The resulting RNA library is ligated with a PEG-Puro spacer and (3) in vitro translated to form a peptide-mRNA
conjugate library. (4) The mRNA-displayed peptide library is incubated with MDM2 immobilized on beads through an affinity selection tag containing
a ZZ domain and a TEV protease cleavage site [25], and unbound molecules are washed away. (5) The bound molecules are eluted by cleavage with
the TEV protease, and (6) their mRNA portion is amplified by RT-PCR. The resulting DNA can be used for the next rounds of selection or analyzed by
cloning and sequencing.
doi:10.1371/journal.pone.0017898.g001
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peptides. Peptide sequences selected from randomized mRNA-
displayed peptide libraries were aligned using the ClustalW program.
The peptide sequences are shown using the single-letter code. (A) 16-
mer peptides selected after four rounds of selection. Three amino acid
residues, Phe, Trp and Leu, which were conserved in nearly every
peptide, are shown in bold. (B) 12-mer peptides after five rounds of
selection. Fixed amino acid residues are shown in bold. Values below
the displayed p5317–28 sequence indicate the position of amino acids in
the p53 protein. (C) Sequence logos representations were created with
webLogo version 2.8.2 (http://weblogo.berkeley.edu/) based on the 83
peptide sequences obtained using the mRNA display system to select
peptides that bound to MDM2 from the 12-mer partially randomized
peptide library. The height of each column reflects the bias of particular
residues. Polar amino acids containing an amide group and the amino
acids that do not contain an amide group are shown in purple and
green, respectively. Acidic and basic charged residues are shown in red
and blue, respectively, while the hydrophobic residues are shown in
black.
doi:10.1371/journal.pone.0017898.g002
Figure 3. Inhibition of MDM2-p53 and MDMX-p53 interactions
by synthetic peptides. (A) GFP-tagged MIP was generated by a
transcription/translation reaction and used for in vitro binding assays as
described in the ‘‘Materials and Methods’’ section. I, input; F, flow-
through; B, beads. (B) MDM2 or (C) MDMX was generated by an in vitro
transcription reaction, bound to His6-p53 immobilized on copper-
coated plates in the presence of various concentrations of synthetic MIP
(circle), DI (triangle), 3A (diamond) or p53 (square) peptides and
quantified by ELISA. The IC50 values are shown in Table 1.
doi:10.1371/journal.pone.0017898.g003
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We tested the ability of MIP to inhibit the MDM2-p53
interaction by an ELISA assay that was capable of detecting
amounts of MDM27–300 bound to immobilized His6-p53 in the
presence of different concentrations of synthetic peptides (Fig. 3B).
In this assay, MIP could inhibit the interaction with an IC50 of
10 nM, which is 29- and 470-fold more potent than the DI and
p5317–28 peptides, respectively (Table 1). Despite not having
selected for binding to MDMX, MIP could also inhibit the
MDMX-p53 interaction at an IC50 of 120 nM, which was 13- and
250-fold more effective than the DI and p5317–28 peptides,
respectively (Fig. 3C). These results supported the previous report
that the binding interactions of p53 to both MDM2 and MDMX
were very similar [26], [27].
To examine what key residue in MIP is responsible for
disrupting the MDM2-p53 interaction, mutational analysis was
performed (Table 1). Six residues in MIP (Phe3, Tyr6, Trp7, Arg9,
Leu10 and Met11) were replaced by Ala because these six sites
were found to be retained in the peptides obtained from the 2nd
selection (Fig. 2C). Replacement of Phe3, Tyr6, Trp7, Leu10 and
Met11 to Ala lowered the inhibitory ability of the peptide 57-,
.10,000-, .10,000-, 114- and 40-fold, respectively. In addition to
the known key residues for binding to MDM2 (Phe3, Tyr6, Trp7
and Leu10), Met11 of MIP was identified as a novel key residue.
The results suggest that the frequency of the amino acid residues at
each position of the peptide enriched from the selection reflects
that position’s importance in determining affinity to the bait.
GFP-MIP interacts with MDM2 and activates the p53
pathway in cultured cells
We tested whether GFP-fused MIP interacted with MDM2 in
living cells. In immunoprecipitation assays, MDM2 was copreci-
pitated with GFP-MIP, but not GFP-FLAG or GFP alone when
expressed in human colon carcinoma HCT116-p53+/+ cells
(Fig. 4A) expressing wild-type p53. We examined the ability of
GFP-MIP to activate the p53 pathway. In contrast to the 16-mer
peptides, expression of GFP-MIP caused an increase in p53 and its
targets (MDM2 and p21) at the protein level in HCT116-p53+/+
cells but not in SW480 cells containing inactive mutated p53
(Fig. 4B), indicating that the induction of MDM2 and p21
expression was dependent on p53 activity. Moreover, quantitative
RT-PCR analysis showed that expression of GFP-MIP increased
MDM2 and p21 at the mRNA level in HCT116-p53+/+ cells,
whereas no effect on a p53 mRNA level was observed (Fig. 4C), as
expected, because the increase in p53 protein level was the result







MIP PRFWEYWLRLME 0.01 0.12
DI LTFEHYWAQLTS 0.29 1.6
3A LTAEHYAAQATS .100 .100
p5317–28 QETFSDLWKLLP 4.7 30
MIP (F3A) PRAWEYWLRLME 0.57 Not tested
MIP (Y6A) PRFWEAWLRLME .100 Not tested
MIP (W7A) PRFWEYALRLME .100 Not tested
MIP (R9A) PRFWEYWLALME 0.02 Not tested
MIP (L10A) PRFWEYWLRAME 1.14 Not tested
MIP (M11A) PRFWEYWLRLAE 0.4 Not tested
doi:10.1371/journal.pone.0017898.t001
Figure 4. Functional analyses of GFP-MIP in living cells. HCT116-
p53+/+ cells or SW480 cells (p53 mt) were transfected with plasmids
encoding GFP-fused MIP, GFP-fused FLAG or GFP alone. (A) Immuno-
precipitation assays with anti-GFP were performed followed by western
blot with an anti-MDM2 antibody. I, input; F, flow-through; B, beads. (B)
The whole cell lysates were analyzed by western blot with antibodies
against p53, MDM2, p21 and b-actin. (C) mRNA levels of p53, MDM2,
p21 and GAPDH were determined by quantitative reverse transcription-
PCR using total RNA extracted from the cells. GAPDH was used for
normalization.
doi:10.1371/journal.pone.0017898.g004
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protein synthesis. However, proliferation of these cells was not
inhibited, presumably due to the low transduction or expression
efficiency of the plasmid (data not shown).
Construction of adenoviruses expressing MIP and its
functional analyses
To overcome the low transduction efficiency of the plasmid
expressing GFP-MIP and for inhibiting tumor cell growth, we
prepared a synthetic MIP fused to Tat, a cell-permeable peptide
(Tat-MIP). However, the peptide could not activate the p53
pathway (Fig. S2A) but induced necrosis, which is independent of
the p53 pathway (Fig. S2B). This result is consistent with previous
reports that a p53 peptide fused to a cell-permeable a-helical
peptide induced necrosis with cell membrane disruption [28], [29].
We next constructed a recombinant adenovirus expressing MIP
fused to a FLAG-tagged thioredoxin scaffold protein (Ad-MIP), as
previously described, [30] based on a Cre/loxP adenovirus system.
Likewise, DI and 3A (LTAEHYAAQATS; a triple mutant of DI
as negative control) expressing adenovirus were constructed (Ad-
DI and Ad-3A, respectively). We initially examined the interaction
between Ad-MIP and MDM2 by immunoprecipitation assays.
The results show that MDM2 coimmunoprecipitated with Ad-
MIP or Ad-DI but not with Ad-3A, indicating that Ad-MIP could
bind to MDM2 in living cells (Fig. 5A). Furthermore, expression of
Ad-MIP increased p53 and its target at the proteins and mRNA
level in HCT116-p53+/+ cells but not in HCT116-p532/2 cells
(Fig. 5B and C). These results show that Ad-MIP could interact
with MDM2 and that the interaction resulted in activation of the
p53 pathway similar to GFP-MIP.
We validated the ability of MIP to inhibit tumor cell growth
following activation of the p53 pathway. At 400 MOI infection of
Ad-MIP, cell growth of HCT116-p53+/+ cells was inhibited to
approximately 50% of control, whereas no inhibition of HCT116-
p532/2 cells was detected (Fig. 6). In a recombinant adenovirus
system we used here, Ad-DI did not inhibit tumor cell growth at
titers of up to 400 MOI. These results suggest that Ad-MIP could
inhibit tumor cell growth in a p53-dependent manner more
potently than Ad-DI.
Discussion
In the development of anticancer drugs, inhibition of the
MDM2-p53 interaction is a very important target. In previous
studies, several MDM2-binding peptides, such as DI, that mimic a
MDM2 binding domain of p53 have been identified by selection
from a randomized library using phage display [12]. Library size
in this selection system has been limited to at most ,10
8 [31]
molecules, whereas the number of possible sequences of 12-mer
randomized peptides is 4.1610
15. These previously identified
peptides were not selected from all of the possible sequences and
therefore may not be optimized for binding to MDM2. In this
study, we performed selection of MDM2-binding peptides from a
random library containing all of the possible sequences by dividing
the selection process into two stages to obtain potent peptides.
While the library size of mRNA display does not cover 4.1610
15
possible sequences, determining key residues that could not be
replaced by other residues resulted in a reduction of the number of
Figure 5. Activation of the p53 pathway by inhibiting the
MDM2-p53 interaction. (A) HCT116-p53+/+ cells were infected with
400 MOI of Ad-3A, DI or MIP and 8 MOI of Ad-Cre. After 48 h,
immunoprecipitation assay with anti-FLAG antibody was performed
followed by western blot with anti-MDM2 or anti-FLAG antibody. (B)
HCT116-p53+/+ or HCT116-p532/2 cells were infected with 50 MOI of
Ad-3A, DI or MIP and 1 MOI of Ad-Cre. After 24 h, the whole cell lysates
were analyzed by western blot with antibodies against p53, p21 and b-
actin. (C) HCT116-p53+/+ or HCT116-p532/2 cells were infected with
50 MOI of Ad-3A, DI or MIP and 1 MOI of Ad-Cre. After 24 h, mRNA
levels of p53, MDM2, p21 and GAPDH were determined by quantitative
reverse transcription-PCR using total RNA extracted from the cells.
GAPDH was used for normalization.
doi:10.1371/journal.pone.0017898.g005
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selection from a partially randomized library led to improvement
of subsequent peptides. Furthermore, by repetition of the selection
round in a stepwise manner, we were able to eventually identify an
optimal peptide with the desired function. Consequently, we
identified MIP as an optimized peptide sequence for binding to
MDM2 from all possible sequences.
It should be noted that we obtained not only MIP but also
peptide X12-2 with approximately the same frequency in the 2nd
selection (Fig. 2B). Although in vitro binding assay showed that
X12-2 binds to MDM2, GFP-X12-2 did not activate p53 pathway
in living cells (data not shown). Therefore, we concluded that MIP
was more potent than X12-2 and identified MIP as an optimal
peptide for inhibiting the MDM2-p53 interaction. Moreover, from
the peptide sequences obtained from the 1st selection (Fig. 2A) as
well as the previous reports [24], we postulated that three
hydrophobic residues corresponding to Phe19, Trp23, and Leu26
of wild-type p53 as the optimal binding motif to bind to MDM2,
and we fixed these residues in the 2nd selection. However, peptide
X16-9 possessed Leu at the position of Trp23, suggesting that
substitution of Trp to Leu is tolerated at the position, and thus the
possibility remains that another optimal peptide will be obtained
from a library with fixed Leu23.
Recently, Zondlo et al. showed that mutation of Pro27Ser in the
p5317–28 peptide enhanced its affinity for MDM2 because the
mutation increased the a-helical property of the p5317–28 peptide
[32]. In this study, we found that Met11 of MIP was important for
binding to MDM2. Because the position of Met11 of MIP
corresponds to Pro27 of p53, the residue might contribute to an
increaseinthea-helicalnatureofthe peptide.Althoughwehavenot
yet determined how Met11 in MIP is involved in binding to
MDM2, structural analyses of MDM2 complexes with selected
peptides in the future will be helpful in determining precisely what
keyresiduesinMIPbind toMDM2.In addition,from the structural
information, low-molecular-weight compounds that mimic MIP
can be designed as in the case of Nutlin-3 [10]. Low-molecular-
weight compounds have several advantages over peptide inhibitors,
such as high cell permeability and low cost. The strategy based on
the three-dimensional conformation of an oncoprotein and a
peptide inhibitor complex will lead to the establishment of a high
throughput system for developing novel anti-cancer drugs.
Although our aim was not to select peptides for binding to the
MDM2 homolog, MDMX, we found that MIP could also inhibit
the MDMX-p53 interaction more effectively than DI. A recent
study revealed that structures in the p53-binding domains of
both MDM2 and MDMX were very similar [27]. The structural
study and our results suggest that the binding affinity of the
peptides to MDM2 is directly proportional to the affinity of the
peptides to MDMX binding. MDMX also binds to p53 and
inhibits the anti-tumor activity as well as MDM2 [33]. As
inhibiting MDM2 or MDMX leads to significant cancer therapy
in vivo, targeting both MDM2 and MDMX was effective for
optimal p53 activation [33]. Therefore, MDM2/MDMX dual
specific inhibitors can be potential cancer therapeutics. Howev-
er, Nutlin-3 cannot bind to MDMX, most likely due to the
presence of various sequence differences in its p53-binding
pocket compared to MDM2 [26], [27]. Although Nutlin-3
mimics key residues involved in the binding to MDM2 (Phe19,
Trp23 and Leu26 of p53), a recent study showed that Tyr100 in
MDM2 accommodates the binding of Nutlin-3, whereas Tyr99
in MDMX causes a steric clash with Nutlin-3 [26]. p14ARF is
known as p53 activator by inhibiting MDM2 [34]. Despite
previous study that showed that p14ARF also bind to both
MDM2 and MDMX, we identified no peptide sequences that
were similar to p14ARF, indicating that p53-derived peptides
are more suitable for inhibiting MDM2- and MDMX-p53
interaction than that of p14ARF.
In this study, we showed the usefulness of mRNA-displayed
peptide selection in multiple stages. Because performing selection
in two stages could decrease possible sequences in a randomized
peptide library, those of a 12-mer partially randomized library
could be easily represented by the library size of mRNA display. In
addition, mRNA display has substantial advantages over phage
display for peptide selection, in which (i) the library size of the
former is much larger than that of the latter, and (ii) cell-free
translation of the former is compatible with the incorporation of
unnatural amino acids [35]–[38].
Materials and Methods
Preparation of bait protein
Oligonucleotides used in this study are presented in Table S1.
The cDNA of MDM2 (7–300 amino acids) was amplified by PCR
using MDM(1–294)-f and MDM(1–294)-r primers from an A549
cell-derived cDNA library. The PCR product was re-amplified by
PCR using 59adaptorO29T7EcoR and Flag1A-lib primers and
cloned into the pDrive cloning vector (Qiagen, Valencia, CA,
USA). From the resulting plasmid, the MDM27–300 coding DNA
was amplified by PCR using Bam-MDM-f and MDM294-Xho-r
primers, digested with BamHI and XhoI, and subcloned into the
BamHI/XhoI site of the pCMV-CBPzz vector [39]. The pCMV-
CBPzz vector contains a SP6 promoter, a part of the omega
sequence named O9 [40], an N-terminal T7-tag coding sequence,
and a C-terminal affinity tag, the coding sequence for the IgG
binding domain of protein A (ZZ domain), a TEV protease
cleavage site and a calmodulin binding peptide [25]. From the
resulting pCMV-MDM294-CBPzz plasmid, a bait template DNA
was amplified by PCR using SP6-O9-T7 and 39FosCBPzz primers.
The PCR product was purified with the QIAquick PCR
purification kit (Qiagen) and used as a template for in vitro
transcription with a RiboMax large-scale RNA production system-
SP6 (Promega, Madison, WI, USA). The RNA was purified with
an RNeasy mini kit (Qiagen) and in vitro-translated in a wheat
germ cell-free translation system (Promega) to produce the MDM2
protein as bait.
Figure 6. Inhibition of cell growth by Ad-MIP. HCT116 cells p53+/+
or p532/2 were infected with the indicated MOI of Ad-3A, DI or MIP and
1/50 MOI of Ad-Cre. After 72 h, cell viability was analyzed by the WST-1
assay.
doi:10.1371/journal.pone.0017898.g006
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libraries
The 16-mer random DNA library was amplified from
G4SG4S(NNS)16FLAGA6r by PCR using priSP6OGf and
priFLAGA6r primers. The 12-mer random DNA library was
amplified from X12(FWL)-r using 59O29-T7-EcoRI and Flag1A-
lib primers. The PCR products were purified with the QIAquick
PCR purification kit and transcribed into RNA. The resulting
RNA was purified with the RNeasy mini kit and ligated with a
PEG-Puro spacer [p(dCp)2-T(Fluor)p-PEGp-(dCp)2-puromycin]
[39] using T4 RNA ligase (Takara, Otsu, Japan). The ligated
RNA was purified with the RNeasy mini kit and in vitro-translated
in the wheat germ cell-free translation system to create the
mRNA-displayed peptide library [39].
Preparation of IgG beads
The IgG-Immutex-MAG beads were prepared as follows.
Twenty milligrams of Immutex-MAG (MAG2101) (JSR, Tokyo,
Japan) were washed three times with PBS containing 0.01%
Triton X-100. EDC (0.25 mg/ml) was subsequently added and
mixed on a rotator for 90 min at room temperature. Chempure
rabbit IgG (Jackson Immunoresearch, West Grove, PA, USA) was
then added and mixed on a rotator for 16 h at room temperature.
After removal of the supernatant, wash buffer (PBS, 0.1% BSA
and 0.01% Triton X-100) was added and incubated for 1 h at
room temperature. The beads were subsequently washed five
times with wash buffer and stored in PBS containing 0.1% BSA,
0.01% Triton X-100 and 0.02% NaN3 at 4uC.
Affinity selection
The bait protein was added to the IgG-Immutex-MAG beads
that had been pre-equilibrated with IPP150 (10 mM Tris-HCl,
pH 8.0, 150 mM NaCl and 0.1% NP-40) and mixed on a rotator
for 1 h at 4uC. The beads were washed three times with IPP150
prior to the addition of the mRNA-displayed peptide library. The
beads/mRNA-displayed peptide library were mixed on a rotator
at 4uC for 10 min (5 min after the third round). The beads were
washed eight times (13 times after the third round) with IPP150
and twice with TEV cleavage buffer (10 mM Tris-HCl, pH 8.0,
150 mM NaCl, 0.1% NP-40, 1 mM DTT and 5 mM EDTA),
and 20 U of TEV protease (Invitrogen, Carlsbad, CA, USA) was
added. Rotation was continued for 2 h at 16uC. The resulting
eluate was used as the RT-PCR template. RT-PCR was
performed with the OneStep RT-PCR kit (Qiagen) using the
59O29-f and 39Flag1A primers. The RT-PCR product was used
for the next round of selection as described above. After five
rounds of affinity selection, the RT-PCR product was cloned
using a PCR cloning kit (Qiagen) and sequenced with an ABI
PRISM 3100 Genetic Analyzer (Applied Biosystems, Foster, CA,
USA).
Preparation of the GFP-fused peptides
Two oligonucleotides, GFP-fus-MIPf and GFP-fus-MIPr, were
phosphorylated with T4 polynucleotide kinase (Takara) followed
by ethanol precipitation. The resulting phosphorylated oligonu-
cleotides were annealed by mixing and heating to 98uC for 20 sec
and gradually cooled to room temperature. The DNA was cloned
into the HindIII/EcoRI site of the pQBI25-HL4 vector [41]. The
pQBI25-HL4-FLAG vector used for expressing GFP-FLAG was
generated as previously described [42]. The resulting pQBI25-
HL4-MIP or pQBI25-HL4-FLAG plasmid was in vitro-transcribed
and translated in a TNT coupled wheat germ extract system
(Promega) to produce GFP-fused peptides.
In vitro binding assay
The GFP-tagged peptide was incubated with MDM2 immobi-
lized on IgG beads for 1 h at 4uC. The beads were washed three
times with IPP150, followed by vortexing to elute the bound
molecules. The resulting eluate was loaded on a 10% SDS-PAGE
gel, and the fluorescence of the GFP tag was detected with a
Molecular-Imager FX (BioRad, Richmond, CA, USA).
ELISA
His6-tagged p53 was expressed in E. coli as follows: The full
length of the p53 gene was cloned into the NdeI/BamHI site of
pET15b (Novagen, San Diego, CA, USA). The resulting plasmid
was transformed into the E. coli strain BL21 (DE3) codon+. The
cells were grown in LB with 50 mg/ml carbenicillin at 37uCt oa n
optical density (OD600) of 0.5 and induced with 1 mM IPTG for
6 h. Inclusion bodies from the medium were lysed with 50 mM
Tris-HCl, pH 8.5, 10 mM DTT and 8 M urea from which the
His6-p53 was prepared. The His6-tagged p53 (2.5 mg/ml PBS) was
immobilized on the wells of Hisgrab copper-coated, high-binding-
capacity plates (Pierce, Waltham, MA, USA) by incubation at 4uC
for 16 h. After washing with PBST, the plates were blocked with
5% skim milk at 4uC for 30 min. In vitro-translated MDM2 (7–300
amino acids) mixed with the synthetic peptides MIP, DI, 3A or
p5317–28 in binding buffer (5% skim milk, 10% glycerol) was added
to the wells. The plates were washed after incubating at room
temperature for 1 h and were subsequently incubated with
antibodies against MDM2 (SMP14, Santa Cruz, Santa Cruz,
CA, USA) or FLAG M2 (Sigma, St. Louis, MO, USA) followed by
incubation with HRP-labeled anti-mouse IgG (Jackson Immunor-
esearch). The binding amount of MDM2 or MDMX was
measured by the ELISA POD substrate TMB kit (Nacalai Tesque,
Kyoto, Japan) with a SAFIRE micro plate reader (Tecan,
Ma ¨nnedorf, Switzerland). To test the ability of the peptides to
inhibit MDMX-p53 interaction, the cDNA of MDMX (1–200
amino acids) was amplified by PCR using the T7-MDMX(1–200)f
primer and the MDMX-(1–200)-FLAG construct from a Human
Mosaic cDNA template (Genofi, San Clemente, CA, USA) and re-
amplified by PCR using 59O29-f and MDMX(1–200)-FLAG. The
PCR product was purified with the QIAquick PCR purification kit
and used as a template for in vitro transcription with the RiboMax
large-scale RNA production system-SP6. The RNA was purified
with the RNeasy mini kit and in vitro-translated in a wheat germ
cell-free translation system to produce MDMX protein.
Cell lines
The tumor cell lines HCT116-p53+/+ and HCT116-p532/2
cells were kindly provided by Dr. Bert Vogelstein (Johns Hopkins
University) and were maintained in McCoy’s 5A medium with
10% fetal bovine serum and 1% penicillin/streptomycin. SW480
cells purchased from the American Type Culture Collection
(ATCC, Manassas, VA, USA) in 2005 and Saos-2 cells purchased
from RIKEN Cell Bank (Ibaraki, Japan) in 2007 were maintained
in DMEM with 10% fetal bovine serum and 1% penicillin/
streptomycin.
Immunoprecipitation assay
HCT116-p53+/+cells were transfected with pQBI25-HL4-MIP
or pQBI25-HL4-FLAG (containing a C-terminal FLAG tag) using
the Lipofectamine2000 reagent (Invitrogen). After 24 h, the cells
in a 60-mm dish were rinsed once with ice-cold PBS and lysed
with 500 ml of TNE buffer (10 mM Tris-HCl, pH 7.8, 150 mM
NaCl, 1 mM EDTA, 1% NP-40). The cells in the suspension were
separated by centrifugation at 12,000 g for 20 min. Twenty
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ical Laboratories, Tokyo, Japan) or anti-FLAG M2 agarose
(Sigma) was added to the resulting supernatant and rotated for
2 h at 4uC. The agarose beads were washed five times with TNE
buffer and resuspended in SDS-PAGE loading buffer for
immunoblot analysis.
Western blot analysis
Whole cell lysate was analyzed by western blot analysis with
antibodies against p53 (Cell signaling, Beverly, MA, Japan),
MDM2 (SMP14, Santa Cruz), p21 (SX118, Pharmingen, San
Diego, CA, USA) and b-actin (AC-15, Sigma). The blots were
developed using an ECL chemiluminescence kit (GE Healthcare,
Waukesha, WI, USA).
Real-time RT-PCR analysis
Total RNA was extracted with the RNeasy mini kit from cells.
The RNA was used as template for the real-time RT-PCR
reaction with the QuantiTect SYBR Green RT-PCR kit (Qiagen)
using the p53F and p53R primer set, the mdm2F and mdm2R
primer set or the p21F and p21R primer set. The GAPDH gene
was used for normalization with the Light cycler primer sets
(Roche, Basel, Switzerland).
Construction of adenoviruses
DNA fragments encoding three peptides, MIP, DI and 3A,
fused to the E. coli thioredoxin scaffold protein were prepared as
previously described [12]. The recombinant adenoviruses express-
ing each of the peptides were generated using the adenovirus Cre/
loxP kit dual version (Takara). These recombinant adenoviruses
were purified by ultracentrifugation on CsCl2 gradients and titered
using the Adeasy viral titer kit (Stratagene, San Diego, CA, USA).
Infection was performed according to the manufacturer’s protocol.
WST-1 assay
Cells (1610
4 cells/well) were seeded in a 96-well plate and
incubated for 24 h to allow them to attach to the plate. The
medium was removed and replaced with fresh medium containing
varying MOIs of recombinant adenovirus or different concentra-
tions of synthetic Tat-MIP. The cells were then incubated for
72 h, and the number of viable cells was determined with the cell
proliferation reagent WST-1 (Roche) according to the manufac-
turer’s protocol.
Supporting Information
Figure S1 In vitro binding assay of GFP-tagged selected
peptides with MDM2-immobilized beads. GFP-tagged
peptides were generated by a transcription/translation reaction
and used for the in vitro binding assay (see Materials and Methods).
I, input; F, flow-through; B, beads.
(TIF)
Figure S2 Tat-MIP induces necrosis of tumor cells
independent of the p53 pathway. (A) HCT116-p53+/+ cells
were treated with DMSO, 10 mM Nutlin-3 or 10 mM synthetic
Tat-MIP for 48 h. Whole cell lysates were analyzed by western
blot with antibodies against p53, MDM2, p21 and b-actin. (B)
HCT116-p53+/+ and HCT116-p532/2 cells were treated with
the indicated concentration of synthetic Tat-MIP for 72 h. Cell
viability was subsequently analyzed using the WST-1 assay.
(TIF)
Table S1 Oligonucleotide sequences used in this study.
(DOC)
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